Aug 11 (Reuters) - OptiNose Inc OPTN.O :
* OPTINOSE REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
AND
OPERATIONAL UPDATES
* Q2 REVENUE ROSE 12 PERCENT TO $20.6 MILLION
* COMPANY PLANS TO SUBMIT AN SNDA FOR XHANCE AS A TREATMENT
FOR
CHRONIC SINUSITIS BY END OF 2022
* COMPANY EXPECTS FULL YEAR 2022 XHANCE NET REVENUE TO BE
BETWEEN
$85 TO $92 MILLION
* COMPANY EXPECTS FULL YEAR 2022 AND OPERATING EXPENSES TO
BE
BETWEEN $129 TO $134 MILLION
* Q2 LOSS PER SHARE $0.23
* Q2 EARNINGS PER SHARE VIEW $-0.24, REVENUE VIEW $20.6
MILLION --
REFINITIV IBES DATA
* FY2022 EARNINGS PER SHARE VIEW $-0.82, REVENUE VIEW $91.1
MILLION -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX2YrPbD
Further company coverage: OPTN.O